Wilson Sonsini Goodrich & Rosati advised Venrock on IP related matters related to the transaction. Lycia Therapeutics, Inc., a biotechnology company, announced it raised $106.6 million...
Lycia Therapeutics’ $106 Million Series C Financing Round
Reneo Pharmaceuticals’ Merger with Onkure
Jones Day and Cooley are representing Reneo Pharmaceuticals, Inc. in the transaction, and Wilson Sonsini Goodrich & Rosati, P.C. is representing OnKure, Inc. Covington & Burling...
Zenas BioPharma’s Upsized $200 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction. Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced an...
Enlaza Therapeutics’ $100 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction. Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it closed...
Reunion Neuroscience’s $103 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, announced the close of a $103 million Series A...
Boundless Bio’s $100 Million IPO
Latham & Watkins and Wilson Sonsini Goodrich & Rosati advised Boundless Bio on the offering, and Cooley advised the underwriters. Boundless Bio, Inc. (Nasdaq: BOLD) a clinical...
vTv Therapeutics’ $51 Million Private Placement Financing
Wilson Sonsini Goodrich & Rosati advised vTv Therapeutics on patent matters related to the transaction. vTv Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of a private...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Avidity Biosciences’ $400 Million Shares Private Placement
Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it has agreed to sell 15,224,773...
Tenaya Therapeutics’ $50 Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised Tenaya Therapeutics on the transaction, and Davis Polk & Wardwell advised the underwriters. Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage...
JIXING’s Collaborations with TMS
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
Insilico Medicine’s License Agreement with Menarini Group
Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...